InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials

Simply Wall St.

07/14

In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2651973109"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651973109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651973109?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-14 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651973109","market":"nz","top_or_hot":-1,"title":"InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials","media":"Simply Wall St.","content":"<div>\n<p>In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-07-14 17:31</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC","symbol_name":"艾格里房產","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente","article_id":"2651973109","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651973109","pubTimestamp":1784021502,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a proprietary payload and protease-cleavable linker for improved stability and safety.\nThis marks an early but important test of InnoCare’s ADC platform against CDH17, a tumor-restricted target relevant to multiple gastrointestinal cancers for which no CDH17 ADCs are yet approved globally.\nNext, we’ll...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADC":"艾格里房产","09969":"诺诚健华","BK7095":"多种金属与采矿","BK4231":"零售房地产信托","ADC.AU":"ACDC Metals Ltd","NETL":"NETLease Corporate Real Estate ETF","BK4080":"零售业房地产投资信托","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"首个 CDH17 ADC 进入人体试验后，诺诚健华 (SEHK:9969) 上涨 6.6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1.5,"ADC.AU":1,"09969":0.9,"NETL":0.6},"content_text":"In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a proprietary payload and protease-cleavable linker for improved stability and safety. This marks an early but important test of InnoCare’s ADC platform against CDH17, a tumor-restricted target relevant to multiple gastrointestinal cancers for which no CDH17 ADCs are yet approved globally. Next, we’ll examine how initiating first-in-human testing of the CDH17-targeted ADC ICP-B208 could influence InnoCare Pharma’s broader investment narrative. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementInnoCare Pharma Investment Narrative RecapTo own InnoCare Pharma, you need to believe its oncology and autoimmune pipeline can offset earnings pressure and justify continued heavy R&D. The first patient dosed with ICP-B208 showcases InnoCare’s early ADC ambitions but does not yet change the near term focus on orelabrutinib data, autoimmunity readouts and managing rising development costs, while ADC execution risk remains a key concern. Among recent announcements, the NDA acceptance in China for orelabrutinib in primary immune thrombocytopenia looks most relevant. It highlights how InnoCare is already trying to broaden its revenue base beyond hematologic cancers, while ICP-B208 extends that diversification effort into solid tumors. Together, these moves frame near term catalysts around regulatory outcomes and commercialization progress versus the ongoing risk of high, pipeline wide R&D spending. Yet, even as pipeline progress excites investors, the sheer scale of R&D commitments is something investors should be aware of... Read the full narrative on InnoCare Pharma (it's free!)InnoCare Pharma's narrative projects CN¥3.8 billion revenue and CN¥205.8 million earnings by 2029. This requires 15.1% yearly revenue growth and an earnings decrease of about CN¥524.5 million from CN¥730.3 million today.Uncover how InnoCare Pharma's forecasts yield a HK$19.62 fair value, a 37% upside to its current price.Exploring Other PerspectivesSEHK:9969 1-Year Stock Price Chart While consensus worries about earnings declining 19.6 percent a year, the most optimistic analysts were assuming revenue could reach about CN¥4.2 billion by 2029, so this new ADC step may eventually shift how you weigh that upside against the very real concentration and R&D risks.Explore another fair value estimate on InnoCare Pharma - why the stock might be worth as much as 37% more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your InnoCare Pharma research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free InnoCare Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnoCare Pharma's overall financial health at a glance.No Opportunity In InnoCare Pharma?Opportunities like this don't last. These are today's most promising picks. Check them out now:Outshine the giants: these 16 early-stage AI stocks could fund your retirement.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}